An 80-year-old man in Texas developed angioedema thought to be triggered by the antipsychotic therapy risperidone, according to a…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to navenibart — the …
People with hereditary angioedema (HAE) in Japan with access to on-demand therapies alone can have a high rate of…
Race and geographic disparities are common in clinical trials of hereditary angioedema (HAE), with non-white patients and countries outside…
People with hereditary angioedema (HAE) typically experience a markedly delayed diagnosis — from three to 26 years following the…
Children in Egypt with hereditary angioedema (HAE) wait an average of three years to be diagnosed, according to a small…
Otsuka Pharmaceutical has obtained exclusive rights to commercialize donidalorsen for hereditary angioedema (HAE) in the Asia-Pacific region. The…
Deucrictibant, an experimental treatment for hereditary angioedema (HAE), now has shown promising efficacy as an on-demand and prophylactic,…
Orladeyo (berotralstat), an oral therapy designed to prevent swelling attacks in adults and adolescents with hereditary angioedema (HAE), has now…
Hereditary angioedema (HAE) is marked by frequent attacks and high disease burden in Canadian patients, who waited a median…